Salute e Benessere
AMP 2025: DNAe to unveil latest data from world's first NGS-based, fully automated sample-to-result diagnostic platform
"We're heading to AMP at a hugely exciting phase in the delivery of our LiDia-SEQ™ diagnostic platform, with news of our latest datasets already generating strong interest across the molecular diagnostics community. Our focus now is on completing the development of our flagship BSI/AMR test on the LiDia-SEQ™ platform – a highly sensitive, fully automated test from whole blood samples that will enable rapid detection and identification of life-threatening infections, bringing unprecedented insights to clinicians when every minute matters."
Category: Infectious Diseases
Presenter: Stephanie Barnes – Scientist, NGS Assay Development, DNAe
Date: Friday November 14 2025,
9:15am – 10:15am EST
Category: Solid Tumors
Presenter: Jarrett Killpack – Future Applications Development Lead, DNAe
Date: Saturday November 15 2025,
9:15am – 10:15am EST
To schedule a meeting with the DNAe team to explore the capabilities of the LiDia-SEQ�� platform, please contact marketing@dnae.com.
DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring. It is developing the LiDia-SEQ™ system, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide comprehensive, actionable information to clinicians in a matter of hours, versus days. DNAe's initial focus is on infectious disease diagnostics, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to directly detect and identify infections that lead to sepsis. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease. A pipeline of follow-on tests is in development for viruses and cancer testing and monitoring. DNAe has received "Breakthrough Device" designation from the US Food and Drug Administration (FDA) for its pioneering platform and first test.
A private company, DNAe has operations in London, UK and Carlsbad, CA , USA. DNAe has received funding from The Biomedical Advanced Research and Development Authority (BARDA) to develop its diagnostic platform, initially for antimicrobial-resistant infections. DNAe's major shareholder is Genting Berhad, a Malaysian-based global investor with a growing portfolio of investments in cutting-edge life sciences companies.
Follow us on LinkedIn and X
View original content:https://www.prnewswire.co.uk/news-releases/amp-2025-dnae-to-unveil-latest-data-from-worlds-first-ngs-based-fully-automated-sample-to-result-diagnostic-platform-302605500.html